NOAC therapy preferred to lower risk of MI in AF | ESC

Danish researchers assessed rivaroxaban, apixaban, and dabigatran vs VKA in patients with non-valvular AF.
Danish researchers assessed rivaroxaban, apixaban, and dabigatran vs VKA in patients with non-valvular AF.